Amgen Inc
featured
Some of the names on the move ahead of the open.
» Read MoreMore
-
A pullback would be healthy for the stock market — and may be overdue, Josh Brown says.
-
Will defensive sectors take another hit on Thursday? Traders will be watching the market. Plus, a big day for earnings, with reports from Exxon, UPS, 3M, Amazon and more.
-
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
-
*Boeing at more than 5- yr high after earnings. NEW YORK, April 24- The S&P 500 and Nasdaq ended flat on Wednesday with Boeing's five-year high among the day's highlights, but weakness in Procter& Gamble and AT&T kept the Dow in negative territory.
-
For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568 For a summary of rating and price target changes on Canadian companies: Reuters Eikon users, click on RCH/CA Reuters 3000 Xtra users, double-click RCH/CA Reuters Station users, click. 4899.
-
The Dow dipped while the S&P 500 edged up on Wednesday as a sharp drop in durable goods orders last month added to worries about slower U.S. economic activity and Apple's results disappointed investors. **BOEING CO, $91.15, up 3.3 pct. **APPLE INC, $401.20, down 1 pct.
-
Shares of Amgen dropped 6 percent to $106.03, weighing on the Nasdaq and the S&P 500 a day after the drug company reported first-quarter sales below analysts' expectations. Helping to limit losses, Boeing jumped 3.4 percent to $91.13 and gave the biggest support to the Dow after the aerospace company reported earnings that beat expectations.
-
Following upbeat earnings, stocks rally for third straight day. Best 3-day winning streak for S&P 500 since late November, best 3-day winning streak for Nasdaq since early August.
-
Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.
-
Stocks ended a volatile day with strong gains Tuesday after taking a sharp nosedive in midday trading, following a false Twitter post of two explosions in the White House.
-
Check out which companies are making headlines after the bell Tuesday:
-
April 23- Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent. Revenue for the quarter rose 5 percent to $4.24 billion, but was shy of Wall Street expectations of $4.37 billion.
-
April 23- Amgen Inc on Tuesday reported higher-than-expected first-quarter profit on increased sales of Enbrel for rheumatoid arthritis and newer medicines to prevent bone fractures, and the company said its full year earnings per share would be above the midpoint of its previously announced forecast.
-
April 23- Amgen Inc on Tuesday reported higher first-quarter profit on increased sales of its drug Enbrel for rheumatoid arthritis and newer medicines to help prevent bone fractures. The world's largest biotechnology company posted a net profit of $1.43 billion, or $1.88 per share, compared with a profit of $1.18 billion, or $1.48 per share, a year ago.
-
U.S. stock index futures pointed to a lower open after dismal Chinese PMI data released early on Tuesday.
-
The earnings train is about to leave the station, with reports due Tuesday from three Dow components, some transportation names and Apple.
-
It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.
-
The "Talking Squawk" blog is meant to be a funny, sarcastic look at business news through the unique "Squawk Box" lens. But it was difficult to think about anything from that viewpoint this week.
-
LONDON, April 19- Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude.
